HEALTHMay 28 · 10:45 UTCNBC NEWSBerkeley Lovelace Jr.

CVS Caremark will cover Lilly’s weight loss drug Zepbound again after patient backlash

CVS Caremark has resumed coverage of Eli Lilly's weight loss drug Zepbound following patient backlash over its initial decision to stop covering the medication. The reversal highlights patient advocacy influencing healthcare policy.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

CVS CaremarkorganizationEli LillyorganizationZepboundtopicpatient backlashtopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHApr 22 · 13:25 UTC
Restrictions on obesity drug coverage force patients to pivot
HEALTHMay 28 · 10:45 UTC
CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans
HEALTHApr 14 · 11:00 UTC
US states drop Medicaid coverage of GLP-1 weight-loss drugs as demand rises
HEALTHApr 15 · 23:00 UTC
Should insurance cover weight loss drugs?
HEALTHMay 13 · 13:28 UTC
STAT+: Pharmalittle: We’re reading about FDA’s Makary resigning, a Lilly weight loss drug trial, and more
HEALTHMay 6 · 09:00 UTC
A New Medicare Option for Weight Loss Drugs: What Older Americans Should Know